Michael Bauer, an experienced biotech entrepreneur, has been appointed chief executive at QUANTRO Therapeutics GmbH, effective 1 May. The Austrian company is working on therapies that interfere with disease-causing transcription factors in cancer. Dr Bauer was previously co-founder and CEO of Cellestia Biotech AG, a spin-off of the Swiss Institute for Experimental Cancer Research. Prior to this, he was head of preclinical and clinical development at Polyphor Ltd, and an oncology portfolio manager at Novartis.
Dr Bauer holds a PhD in biotechnology from the Hamburg University of Technology in Germany.
QUANTRO announced the appointment on 4 April 2023.
Copyright 2023 Evernow Publishing Ltd